Total cohort n (%) | fPSM n (%) | ePSM n (%) | p | |
---|---|---|---|---|
Patients (n) | 189 | 115 (60.9) | 74 (39.1) | |
Mean age (standard deviation) | 71.8 (+/−6.3) | 70.3 (+/−7.5) | 74.1 (+/−8.3) | 0.006 |
Mean PSA (standard deviation) | 8.8 (+/−4.3) | 8.1 (+/−3.6) | 10.0 (+/−4.9) | 0.003 |
Gleason Score (pG) | 0.14 | |||
≤ 6 | 63 (33.3) | 43 (37.4) | 20 (27) | |
7 | 119 (63) | 68 (59.1) | 51 (68.9) | |
3 + 4 | 96 (49.2) | 57 (49.6) | 36 (48.6) | |
4 + 3 | 23 (13.8) | 11 (9.6) | 15 (20.3) | |
≥8 | 7 (3.7) | 4 (3.5) | 3 (4) | |
pT Stage | 0.61 | |||
T2a | 15 (7.9) | 9 (7.8) | 6 (8.1) | |
T2b | 24 (12.7) | 16 (13.9) | 8 (10.8) | |
T2c | 101 (53.4) | 64 (55.6) | 37 (50) | |
T3a | 49 (25.9) | 26 (22.6) | 23 (31.1) | |
Median follow-up (months) | 101.1 | 95.3 | 110.3 | 0.08 |